These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21109448)

  • 1. Monoclonal antibodies against EGFR in non-small cell lung cancer.
    Pirker R; Filipits M
    Crit Rev Oncol Hematol; 2011 Oct; 80(1):1-9. PubMed ID: 21109448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
    Filipits M
    J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer.
    Di Maio M
    Expert Opin Biol Ther; 2011 Sep; 11(9):1131-3. PubMed ID: 21806477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab in non-small-cell lung cancer.
    Carillio G; Montanino A; Costanzo R; Sandomenico C; Piccirillo MC; Di Maio M; Daniele G; Giordano P; Bryce J; Normanno N; Rocco G; Perrone F; Morabito A
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):163-75. PubMed ID: 22316364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a role for cetuximab in non small cell lung cancer?
    Morgensztern D; Govindan R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4602-5. PubMed ID: 17671149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
    Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
    Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.
    Agelaki S; Georgoulias V
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):855-74. PubMed ID: 16262567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR-directed monoclonal antibodies in non-small cell lung cancer.
    Pirker R
    Target Oncol; 2013 Mar; 8(1):47-53. PubMed ID: 23300028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
    O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R
    Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving role of cetuximab in non-small cell lung cancer.
    Lilenbaum RC
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4432s-4435s. PubMed ID: 16857823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.
    Pirker R
    Curr Opin Oncol; 2015 Mar; 27(2):87-93. PubMed ID: 25636162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current status of targeted therapy for non-small cell lung cancer.
    Francis H; Solomon B
    Intern Med J; 2010 Sep; 40(9):611-8. PubMed ID: 20002849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab in advanced non-small cell lung cancer.
    Rossi A; Maione P; Gridelli C
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):139-49. PubMed ID: 16806963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab in advanced non-small cell lung cancer.
    Govindan R
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4241s-4244s. PubMed ID: 15217966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.
    Douillard JY; Pirker R; O'Byrne KJ; Kerr KM; Störkel S; von Heydebreck A; Grote HJ; Celik I; Shepherd FA
    J Thorac Oncol; 2014 May; 9(5):717-24. PubMed ID: 24662454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.
    Pujol JL; Pirker R; Lynch TJ; Butts CA; Rosell R; Shepherd FA; Vansteenkiste J; O'Byrne KJ; de Blas B; Heighway J; von Heydebreck A; Thatcher N
    Lung Cancer; 2014 Feb; 83(2):211-8. PubMed ID: 24332319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging profile of cetuximab in non-small cell lung cancer.
    Ettinger DS
    Lung Cancer; 2010 Jun; 68(3):332-7. PubMed ID: 19783064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies around the use of monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
    Dediu M; Ion O; Ion R; Gal C; Median D; Gongu M
    J BUON; 2009 Sep; 14 Suppl 1():S159-64. PubMed ID: 19785059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel drugs against non-small-cell lung cancer.
    Pirker R
    Curr Opin Oncol; 2014 Mar; 26(2):145-51. PubMed ID: 24406751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.